Esterase-Responsive Fluorogenic Prodrugs of Aldose Reductase Inhibitor Epalrestat: An Innovative Strategy toward Enhanced Anticancer Activity
Roopjyoti Misra,
Pallavi Barman,
Krishna P. Bhabak
Abstract:In addition to the conventional chemotherapeutic
drugs,
potent
inhibitors of key enzymes that are differentially overexpressed in
cancer cells and associated with its progression are often considered
as the drugs of choice for treating cancer. Aldose reductase (AR),
which is primarily associated with complications of diabetes, is
known to be closely related to the development of cancer and drug
resistance. Epalrestat (EPA), an FDA-approved drug, is a potent inhibitor
of AR and exhibits anticancer activity. Ho… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.